Direct-acting agents for hepatitis C virus before and after liver transplantation

Sugawara, Yasuhiko; Hibi, Taizo

doi:10.5582/bst.2017.01293

Cited by 9 publications

(18 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Without curative therapies including liver transplantation, re-infection with HCV occurs in high frequency and commonly results in significant liver graft destruction, resulting in poor patient survival[ 55 ]. Approximately 80% of patients will develop allograft hepatitis within two years of liver transplantation without eradication, and 20% of those patients progress to advanced fibrosis or cirrhosis within five years of transplantation[ 56 ].…”

Section: Liver Transplantation In the Context Of Hcvmentioning

confidence: 99%

“…Approximately 80% of patients will develop allograft hepatitis within two years of liver transplantation without eradication, and 20% of those patients progress to advanced fibrosis or cirrhosis within five years of transplantation[ 56 ]. Of note, cholestatic hepatitis C, which can occur in up to 5% to 10% of patients within one year of liver transplantation, can be rapidly progressive and life-threatening[ 55 ]. For this reason, many eligible patients will undergo treatment with DAAs prior to or following liver transplantation, ideally before recurrence[ 55 ].…”

Section: Liver Transplantation In the Context Of Hcvmentioning

confidence: 99%

“…Of note, cholestatic hepatitis C, which can occur in up to 5% to 10% of patients within one year of liver transplantation, can be rapidly progressive and life-threatening[ 55 ]. For this reason, many eligible patients will undergo treatment with DAAs prior to or following liver transplantation, ideally before recurrence[ 55 ].…”

Section: Liver Transplantation In the Context Of Hcvmentioning

confidence: 99%

“…Although the optimal timing of DAAs in the context of liver transplantation is still to be clarified, many eligible patients receive treatment prior to transplantation. The overall low burden of DDIs with widely used immunosuppressants poses no contraindication for use in the post-transplantation period[ 55 ]. The advantages of early or pre-transplantation viral eradication can include improved overall liver function, quality of life and liver-related complications, potential avoidance of the need for liver transplantation, and lower rate of post-transplantation infection recurrence[ 56 ].…”

Section: Liver Transplantation In the Context Of Hcvmentioning

confidence: 99%

See 3 more Smart Citations

New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years

Dennis¹,

Naji²,

Jajarmi³

et al. 2021

WJG

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a global health concern associated with significant morbidity and mortality. Before the approval of second-generation direct-acting antiviral agents (DAAs), interferon therapy and liver transplantation constituted the mainstay of treatment. The introduction of well-tolerated oral DAAs in late 2013 has revolutionized HCV management with over 95% cure rates. The predominance of HCV-related liver transplantations has declined following the widespread approval of DAAs. Despite the unparallel efficacy observed among these novel therapies, pharmaceutical costs continue to limit equitable access to healthcare and likely contribute to the differential HCV infection rates observed globally. To reduce the burden of disease worldwide, essential agenda items for all countries must include the prioritization of integrated care models and access to DAAs therapies. Through transparent negotiations with the pharmaceutical industry, the consideration for compassionate release of medications to promote equitable division of care is paramount. Here we provide a literature review of HCV, changes in epidemiologic trends, access issues for current therapies, and global inequities in disease burden.

show abstract

Section: Liver Transplantation In the Context Of Hcvmentioning

confidence: 99%

Section: Liver Transplantation In the Context Of Hcvmentioning

confidence: 99%

Section: Liver Transplantation In the Context Of Hcvmentioning

confidence: 99%

Section: Liver Transplantation In the Context Of Hcvmentioning

confidence: 99%

See 2 more Smart Citations

New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years

Dennis¹,

Naji²,

Jajarmi³

et al. 2021

WJG

View full text Add to dashboard Cite

show abstract

“…As to hepatitis C, now direct antiviral agents (DAA) have enabled us effective treatment for patients who underwent liver transplantation for hepatitis C virus related cirrhosis [23] . The currently available direct antiviral agents achieve a satisfactory sustained viral response in post-liver transplantation patients [24] . Optimal timing of the DAA treatment is not yet established, but it may be appropriate to consider DAA treatment after the patients' condition and graft function become stable.…”

Section: Antiviral Therapymentioning

confidence: 99%

Living donor liver transplantation for patients with hepatocellular carcinoma in Japan

Sugawara¹,

Yamamoto²,

Hibi³

2018

Self Cite

View full text Add to dashboard Cite

Liver transplantation has now been an established treatment for hepatocellular carcinoma and cirrhosis. The Milan criteria have been accepted and applied widely in the world as an indication for deceased donor liver transplant.Due to the severe organ shortage, however, living donor liver transplant (LDLT) has accounted for the majority of transplantations in Japan and the other Asian countries/regions. LDLT cannot be limited by the restrictions imposed by the allocation system but depends on institutional criterion or case-by-case considerations. Accumulating data from a nationwide survey and each center experience have indicated that extending the Milan criteria is warranted.

show abstract

Cytokines and serum amyloid A in the pathogenesis of hepatitis C virus infection

Salama

Lavie

Buck

et al. 2019

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Direct-acting agents for hepatitis C virus before and after liver transplantation

Cited by 9 publications

References 45 publications

New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years

New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years

Living donor liver transplantation for patients with hepatocellular carcinoma in Japan

Cytokines and serum amyloid A in the pathogenesis of hepatitis C virus infection

Contact Info

Product

Resources

About